CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mirati Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mirati Therapeutics Inc
3545 Cray Court
Phone: (858) 332-3410p:858 332-3410 SAN DIEGO, CA  92121  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 1/23/2024.
This company ceased filing statements with the SEC on 2/2/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Lead Independent Chairman of the Board FaheemHasnain 64 2/15/2022 2/15/2019
President, Chief Executive Officer, Founder, Director, Head - Research and Development Charles M.Baum 65 8/7/2023 11/12/2012
Interim Chief Financial Officer AaronOndrey 47 9/8/2023 9/8/2023
8 additional Officers and Directors records available in full report.

Business Names
Business Name
MethylGene Inc.
Mirati Therapeutics (Suisse) GmbH
Mirati Therapeutics B.V.

General Information
Number of Employees: 587 (As of 12/31/2022)
Outstanding Shares: 70,147,706 (As of 11/1/2023)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 462693615
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 16, 2024